No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
News Item
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017081/
http://dx.doi.org/10.1007/s40278-021-93387-2
_version_ 1783673985170407424
collection PubMed
description
format Online
Article
Text
id pubmed-8017081
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80170812021-04-02 No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine Reactions Weekly News Item Springer International Publishing 2021-04-03 2021 /pmc/articles/PMC8017081/ http://dx.doi.org/10.1007/s40278-021-93387-2 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
title No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
title_full No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
title_fullStr No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
title_full_unstemmed No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
title_short No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
title_sort no increased risk of anaphylaxis with astrazeneca covid-19 vaccine
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017081/
http://dx.doi.org/10.1007/s40278-021-93387-2

Ejemplares similares